STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The archive — 2025
Page 54 of 68 of this archive, newest first.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
The limits of mechanism: why receptor data will not tell you who responds
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURPASS-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Portugal declines to reimburse semaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The submitted sample: the weakest link in the whole system
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
Five lines that would change what a certificate is worth
None of what this piece asks for is commercially sensitive, and all of it is already known to whoever released the batch.
A shortage listing ends. 12 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
What a 9% rise in coupling-reagent prices does to a 30 mg vial
Follow the resin, not the catalogue.
Australia caps exenatide prescribing to 15 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Tolerability is the ceiling, and the ceiling is personal
An effect is dose-limiting when it prevents adequate intake, prevents normal activity, or produces a risk of its own. Discomfort alone is not the test.
The supply gap as a clinical event
The trials studied planned withdrawal. Almost nobody stops that way.
TRIUMPH-1 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
TRIUMPH-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Portugal declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Antiemetics, laxatives and the thin literature underneath them
Constipation is the most tractable of the effects and the most consistently under-managed.
Not everybody regains at the same rate, and nobody knows why
What returns, in what order, and how much of the benefit survives.
A spectrum is a photograph of an ion, not of a molecule
A brief and unromantic tour of the interface between a liquid sample and a vacuum.
SURPASS-2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The 30-day notice: how a compounding wind-down works in Norway
The document is four pages. Three of them are about dates.
Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a ERP orforglipron lot at 97.4%, against 93.4% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
What VendorInvestigate is able to certify about a sealed vial, and what it is not
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
The United Arab Emirates caps semaglutide prescribing to 14 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Six things incretin pharmacology cannot currently predict
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.